Minimal doses of a sequence-optimized transgene mediate high-level and long-term EPO expression in vivo: Challenging CpG-free gene design

Gene Therapy

Volumn 18, Issue 2, 2011, Pages 189-198

  Kosovac, D ^a   Wild, J ^a   Ludwig, C ^b   Meissner, S ^b   Bauer, A P ^a   Wagner, R ^a,b  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b Geneart AG   (Germany)

Author keywords

codon optimization; CpG dinucleotides; electro gene transfer; erythropoietin; in vivo transfection; transgene expression

Indexed keywords

DINUCLEOTIDE; ERYTHROPOIETIN; HEMOGLOBIN; RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CODON; CONTROLLED STUDY; CPG ISLAND; CYTOPLASM; DRUG DESIGN; GENE SEQUENCE; GENE TRANSFER; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HEMATOCRIT; IN VITRO STUDY; IN VIVO STUDY; MITOSIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MODIFICATION; RNA ANALYSIS; SKELETAL MUSCLE; TRANSGENE;

ANIMALS; CODON; CPG ISLANDS; ELECTROPORATION; ERYTHROPOIETIN; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; MICE; MICE, INBRED BALB C; MUSCLE, SKELETAL; TRANSFECTION; TRANSGENES;

MURINAE;

EID: 79951516590     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2010.134     Document Type: Article

References (60)

1. Smith LC, Nordstrom JL. Advances in plasmid gene delivery and expression in skeletal muscle. Curr Opin Mol Ther 2000; 2: 150-154. (Pubitemid 30212263)
2. Nishikawa M, Hashida M. Nonviral approaches satisfying various requirements for effective in vivo gene therapy. Biol Pharm Bull 2002; 25: 275-283. (Pubitemid 39663276)
3. Glover DJ, Lipps HJ, Jans DA. Towards safe, non-viral therapeutic gene expression in humans. Nat Rev Genet 2005; 6: 299-310. (Pubitemid 40469049)
4. Fattori E, La Monica N, Ciliberto G, Toniatti C. Electro-gene-transfer: a new approach for muscle gene delivery. Somat Cell Mol Genet 2002; 27: 75-83.
5. Richard-Fiardo P, Payen E, Chevre R, Zuber J, Letrou-Bonneval E, Beuzard Y et al. Therapy of anemia in kidney failure, using plasmid encoding erythropoietin. Hum Gene Ther 2008; 19: 331-342. (Pubitemid 351591425)
6. Al Dosari MS, Gao X. Nonviral gene delivery: principle, limitations, and recent progress. AAPS J 2009; 11: 671-681.
7. Mir LM, Bureau MF, Gehl J, Rangara R, Rouy D, Caillaud JM et al. High-efficiency gene transfer into skeletal muscle mediated by electric pulses. Proc Natl Acad Sci USA 1999; 96: 4262-4267. (Pubitemid 29190324)
8. Rizzuto G, Cappelletti M, Maione D, Savino R, Lazzaro D, Costa P et al. Efficient and regulated erythropoietin production by naked DNA injection and muscle electro-poration. Proc Natl Acad Sci USA 1999; 96: 6417-6422. (Pubitemid 29256680)
9. Aihara H, Miyazaki J. Gene transfer into muscle by electroporation in vivo. Nat Biotechnol 1998; 16: 867-870. (Pubitemid 28405859)
10. Mairhofer J, Grabherr R. Rational vector design for efficient non-viral gene delivery: challenges facing the use of plasmid DNA. Mol Biotechnol 2008; 39: 97-104.
11. Yew NS. Controlling the kinetics of transgene expression by plasmid design. Adv Drug Deliv Rev 2005; 57: 769-780. (Pubitemid 40332602)
12. Van Gaal EV, Hennink WE, Crommelin DJ, Mastrobattista E. Plasmid engineering for controlled and sustained gene expression for nonviral gene therapy. Pharm Res 2006; 23: 1053-1074. (Pubitemid 43946132)
13. Kim CH, Oh Y, Lee TH. Codon optimization for high-level expression of human erythropoietin (EPO) in mammalian cells. Gene 1997; 199: 293-301. (Pubitemid 27448231)
14. Graf M, Deml L, Wagner R. Codon-optimized genes that enable increased heterologous expression in mammalian cells and elicit efficient immune responses in mice after vaccination of naked DNA. Methods Mol Med 2004; 94: 197-210.
15. Gustafsson C, Govindarajan S, Minshull J. Codon bias and heterologous protein expression. Trends Biotechnol 2004; 22: 346-353. (Pubitemid 38887543)
16. Duan J, Antezana MA. Mammalian mutation pressure, synonymous codon choice, and mRNA degradation. J Mol Evol 2003; 57: 694-701. (Pubitemid 37543983)
17. Graf M, Schödl T, Wagner R. Rationals of gene design and De novo gene constructions. In: Fu P, Latterich M, Panke S (eds). Systems Biology and Synthetic Biology. John Wiley: New York, 2009, pp 411-438.
18. Kako K, Nishikawa M, Yoshida H, Takakura Y. Effects of inflammatory response on in vivo transgene expression by plasmid DNA in mice. J Pharm Sci 2008; 97: 3074-3083.
19. Scheule RK. The role of CpG motifs in immunostimulation and gene therapy. Adv Drug Deliv Rev 2000; 44: 119-134.
20. Hodges BL, Taylor KM, Joseph MF, Bourgeois SA, Scheule RK. Long-term transgene expression from plasmid DNA gene therapy vectors is negatively affected by CpG dinucleotides. Mol Ther 2004; 10: 269-278. (Pubitemid 39117873)
21. Yew NS, Zhao H, Przybylska M, Wu IH, Tousignant JD, Scheule RK et al. CpG-depleted plasmid DNA vectors with enhanced safety and long-term gene expression in vivo. Mol Ther 2002; 5: 731-738. (Pubitemid 34619066)
22. Mitsui M, Nishikawa M, Zang L, Ando M, Hattori K, Takahashi Y et al. Effect of the content of unmethylated CpG dinucleotides in plasmid DNA on the sustainability of transgene expression. J Gene Med 2009; 11: 435-443.
23. Chevalier-Mariette C, Henry I, Montfort L, Capgras S, Forlani S, Muschler J et al. CpG content affects gene silencing in mice: evidence from novel transgenes. Genome Biol 2003; 4: R53.
24. Dalle B, Rubin JE, Alkan O, Sukonnik T, Pasceri P, Yao S et al. eGFP reporter genes silence LCRbeta-globin transgene expression via CpG dinucleotides. Mol Ther 2005; 11: 591-599. (Pubitemid 40353116)
25. De Wolf HK, Johansson N, Thong AT, Snel CJ, Mastrobattista E, Hennink WE et al. Plasmid CpG depletion improves degree and duration of tumor gene expression after intravenous administration of polyplexes. Pharm Res 2008; 25: 1654-1662.
26. Ill CR, Chiou HC. Gene therapy progress and prospects: recent progress in transgene and RNAi expression cassettes. Gene Ther 2005; 12: 795-802. (Pubitemid 40762555)
27. Bauer AP, Leikam D, Krinner S, Notka F, Ludwig C, Langst G et al. The impact of intragenic CpG content on gene expression. Nucleic Acids Res 2010; 38: 3891-3908.
28. Muramatsu T, Arakawa S, Fukazawa K, Fujiwara Y, Yoshida T, Sasaki R et al. In vivo gene electroporation in skeletal muscle with special reference to the duration of gene expression. Int J Mol Med 2001; 7: 37-42.
29. Chen ZY, He CY, Meuse L, Kay MA. Silencing of episomal transgene expression by plasmid bacterial DNA elements in vivo. Gene Ther 2004; 11: 856-864. (Pubitemid 38714589)
30. Hong K, Sherley J, Lauffenburger DA. Methylation of episomal plasmids as a barrier to transient gene expression via a synthetic delivery vector. Biomol Eng 2001; 18: 185-192. (Pubitemid 32888362)
31. Hyde SC, Pringle IA, Abdullah S, Lawton AE, Davies LA, Varathalingam A et al. CpG-free plasmids confer reduced inflammation and sustained pulmonary gene expression. Nat Biotechnol 2008; 26: 549-551. (Pubitemid 351668040)
32. Wolff JA, Ludtke JJ, Acsadi G, Williams P, Jani A. Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle. Hum Mol Genet 1992; 1: 363-369.
33. Kreiss P, Bettan M, Crouzet J, Scherman D. Erythropoietin secretion and physiological effect in mouse after intramuscular plasmid DNA electrotransfer. J Gene Med 1999; 1: 245-250. (Pubitemid 129631117)
34. MacColl GS, Goldspink G, Bouloux PM. Using skeletal muscle as an artificial endocrine tissue. J Endocrinol 1999; 162: 1-9. (Pubitemid 29336349)
35. Taylor J, Babbs CF, Alzghoul MB, Olsen A, Latour M, Pond AL et al. Optimization of ectopic gene expression in skeletal muscle through DNA transfer by electroporation. BMC Biotechnol 2004; 4: 11.
36. Osborne WR, Ramesh N, Lau S, Clowes MM, Dale DC, Clowes AW. Gene therapy for long-term expression of erythropoietin in rats. Proc Natl Acad Sci USA 1995; 92: 8055-8058.
37. Dubé S, Fisher JW, Powell JS. Glycosylation at specific sites of erythropoietin is essential for biosynthesis, secretion, and biological function. J Biol Chem 1988; 263: 17516-17521. (Pubitemid 19029333)
38. Hojman P, Gissel H, Gehl J. Sensitive and precise regulation of haemoglobin after gene transfer of erythropoietin to muscle tissue using electroporation. Gene Ther 2007; 14: 950-959. (Pubitemid 46865506)
39. Sebestyen MG, Hegge JO, Noble MA, Lewis DL, Herweijer H, Wolff JA. Progress toward a nonviral gene therapy protocol for the treatment of anemia. Hum Gene Ther 2007; 18: 269-285. (Pubitemid 46626465)
40. Maruyama H, Ataka K, Gejyo F, Higuchi N, Ito Y, Hirahara H et al. Long-term production of erythropoietin after electroporation-mediated transfer of plasmid DNA into the muscles of normal and uremic rats. Gene Ther 2001; 8: 461-468. (Pubitemid 32273125)
41. Fattori E, Cappelletti M, Zampaglione I, Mennuni C, Calvaruso F, Arcuri M et al. Gene electro-transfer of an improved erythropoietin plasmid in mice and non-human primates. J Gene Med 2005; 7: 228-236. (Pubitemid 40348027)
42. Terada Y, Tanaka H, Okado T, Shimamura H, Inoshita S, Kuwahara M et al. Ligand-regulatable erythropoietin production by plasmid injection and in vivo electroporation. Kidney Int 2002; 62: 1966-1976. (Pubitemid 35366152)
43. Payen E, Bettan M, Rouyer-Fessard P, Beuzard Y, Scherman D. Improvement of mouse beta-thalassemia by electrotransfer of erythropoietin cDNA. Exp Hematol 2001; 29: 295-300. (Pubitemid 32220120)
44. Fabre EE, Bigey P, Beuzard Y, Scherman D, Payen E. Careful adjustment of Epo non-viral gene therapy for beta-thalassemic anaemia treatment. Genet Vaccines Ther 2008; 6: 10.
45. Hojman P, Zibert JR, Gissel H, Eriksen J, Gehl J. Gene expression profiles in skeletal muscle after gene electrotransfer. BMC Mol Biol 2007; 8: 56.
46. Hartikka J, Sukhu L, Buchner C, Hazard D, Bozoukova V, Margalith M et al. Electro-poration-facilitated delivery of plasmid DNA in skeletal muscle: plasmid dependence of muscle damage and effect of poloxamer 188. Mol Ther 2001; 4: 407-415. (Pubitemid 33100278)
47. Durieux AC, Bonnefoy R, Busso T, Freyssenet D. In vivo gene electrotransfer into skeletal muscle: effects of plasmid DNA on the occurrence and extent of muscle damage. J Gene Med 2004; 6: 809-816. (Pubitemid 40228097)
48. Yew NS, Cheng SH. Reducing the immunostimulatory activity of CpG-containing plasmid DNA vectors for non-viral gene therapy. Expert Opin Drug Deliv 2004; 1: 115-125. (Pubitemid 40297960)
49. Tripathy SK, Goldwasser E, Lu MM, Barr E, Leiden JM. Stable delivery of physiologic levels of recombinant erythropoietin to the systemic circulation by intramuscular injection of replication-defective adenovirus. Proc Natl Acad Sci USA 1994; 91: 11557-11561. (Pubitemid 24356383)
50. Rivera VM, Gao GP, Grant RL, Schnell MA, Zoltick PW, Rozamus LW et al. Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer. Blood 2005; 105: 1424-1430. (Pubitemid 40223657)
51. Maione D, Wiznerowicz M, Delmastro P, Cortese R, Ciliberto G, La Monica N et al. Prolonged expression and effective readministration of erythropoietin delivered with a fully deleted adenoviral vector. Hum Gene Ther 2000; 11: 859-868. (Pubitemid 30202477)
52. Chenuaud P, Larcher T, Rabinowitz JE, Provost N, Cherel Y, Casadevall N et al. Autoimmune anemia in macaques following erythropoietin gene therapy. Blood 2004; 103: 3303-3304. (Pubitemid 38525656)
53. Gao G, Lebherz C, Weiner DJ, Grant R, Calcedo R, McCullough B et al. Erythropoietin gene therapy leads to autoimmune anemia in macaques. Blood 2004; 103: 3300-3302. (Pubitemid 38525655)
54. Lufino MM, Edser PA, Wade-Martins R. Advances in high-capacity extrachromosomal vector technology: episomal maintenance, vector delivery, and transgene expression. Mol Ther 2008; 16: 1525-1538.
55. Miklavcic D, Semrov D, Mekid H, Mir LM. A validated model of in vivo electric field distribution in tissues for electrochemotherapy and for DNA electrotransfer for gene therapy. Biochim Biophys Acta 2000; 1523: 73-83.
56. Clackson T. Regulated gene expression systems. Gene Ther 2000; 7: 120-125. (Pubitemid 30088958)
57. Raab D, Graf M, Notka F, Schoedl T, Wagner R. The GeneOptimizer Algorithm: using a sliding window approach to cope with the vast sequence space in multiparameter DNA sequence optimization. Syst Synth Biol 2010; doi:10.1007/s11693-010-9062-3.
58. Wyatt LS, Moss B, Rozenblatt S. Replication-deficient vaccinia virus encoding bacteriophage T7 RNA polymerase for transient gene expression in mammalian cells. Virology 1995; 210: 202-205.
59. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29: e45.
60. Sharp PM, Li WH. The codon Adaptation Index-a measure of directional synonymous codon usage bias, and its potential applications. Nucleic Acids Res 1987; 15: 1281-1295.